Patents by Inventor Gilles Bignan

Gilles Bignan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CYCLIC DINUCLEOTIDES AS STING AGONISTS
    Publication number: 20230287034
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R1, R1?, X1, B1, R2, R2?, B2, X2, R3, Z-M-Y, and Y1-M1-Z1 are as defined herein.
    Type: Application
    Filed: March 3, 2023
    Publication date: September 14, 2023
    Inventors: Stuart Emanuel, Mark Richter, Peter J. Connolly, James P. Edwards, Guangyi Wang, Santhosh Kumar Thatikonda, Leonid Beigelman, Gilles Bignan, Wim Bert Griet Schepens, Marcel Viellevoye, Johannes Wilhelmus J.F. Thuring
  • CYCLIC DINUCLEOTIDES AS STING AGONISTS
    Publication number: 20230146410
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R, R1B, R1C, R2B, R2C, B1, W, X, Y, Z are defined herein.
    Type: Application
    Filed: November 7, 2022
    Publication date: May 11, 2023
    Inventors: Stuart Emanuel, Mark Richter, Peter J. Connolly, James Patrick Edwards, Guangyi Wang, Santhosh Kumar Thatikonda, Leonid Beigelman, Minghong Zhong, Gilles Bignan, Wim Schepens, Marcel Viellevoye, Johannes Wilhelmus John Fitzgerald Thuring
  • Cyclic Dinucleotides As Sting Agonists
    Publication number: 20230144627
    Abstract: Disclosed are compounds, compositions and methods for treating viral infections, diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R1A, R1B, R1C, B1, R2A, and R2B are defined herein.
    Type: Application
    Filed: October 17, 2022
    Publication date: May 11, 2023
    Inventors: Gilles Bignan, Peter Connolly, James Patrick Edwards, Stuart Emanuel, Sylvie Laquerre, Tianbao Lu, Mark Richter, Leonid Beigelman, Santhosh Kumar Thatikonda, Guangyi Wang, Minghong Zhong
  • Cyclic dinucleotides as sting agonists
    Patent number: 11597746
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I), wherein R1, R1?, X1, B1, R2, R2?, B2, X2, R3, Z-M-Y, and Y1-M1-Z1 are as defined herein.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: March 7, 2023
    Assignee: Janssen Biotech, Inc.
    Inventors: Stuart Emanuel, Mark Richter, Peter J. Connolly, James P. Edwards, Guangyi Wang, Santhosh Kumar Thatikonda, Leonid Beigelman, Gilles Bignan, Wim Bert Griet Schepens, Marcel Viellevoye, Johannes Wilhelmus J. F. Thuring
  • Cyclic dinucleotides as sting agonists
    Patent number: 11492367
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R, R1B, R1C, R2B, R2C, B1, W, X, Y, Z are defined herein.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: November 8, 2022
    Assignee: Janssen Biotech, Inc.
    Inventors: Stuart Emanuel, Mark Richter, Peter J. Connolly, James Patrick Edwards, Guangyi Wang, Santhosh Kumar Thatikonda, Leonid Beigelman, Minghong Zhong, Gilles Bignan, Wim Schepens, Marcel Viellevoye, Johannes Wilhelmus John Fitzgerald Thuring
  • Cyclic dinucleotides as sting agonists
    Patent number: 11472830
    Abstract: Disclosed are compounds, compositions and methods for treating viral infections, diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R1A, R1B, R1c, B1, R2A, and R2B are defined herein.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: October 18, 2022
    Assignee: Janssen Biotech, Inc.
    Inventors: Gilles Bignan, Peter Connolly, James Patrick Edwards, Stuart Emanuel, Sylvie Laquerre, Tianbao Lu, Mark Richter, Leonid Beigelman, Santhosh Kumar Thatikonda, Guangyi Wang, Minghong Zhong
  • CYCLIC DINUCLEOTIDES AS STING AGONISTS
    Publication number: 20210277046
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I), wherein R1, R1?, X1, B1, R2, R2?, B2, X2, R3, Z-M-Y, and Y1-M1-Z1 are as defined herein.
    Type: Application
    Filed: July 16, 2019
    Publication date: September 9, 2021
    Inventors: Stuart Emanuel, Mark Richter, Peter J. Connolly, James P. Edwards, Guangyi Wang, Santhosh Kumar Thatikonda, Leonid Beigelman, Gilles Bignan, Wim Bert Griet Schepens, Marcel Viellevoye, Johannes Wilhelmus J.F. Thuring
  • Cyclic dinucleotides as sting agonists
    Patent number: 11021511
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R1A, R1B, R1C, R1D, B1, R2A, R2B, R2C, R2D, and R2E are defined herein and Formula (II) wherein R1H, R1K, R1J, and R2L are defined herein.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: June 1, 2021
    Assignee: Janssen Biotech, Inc.
    Inventors: Stuart Emanuel, Mark Richter, Peter J. Connolly, James Patrick Edwards, Guangyi Wang, Santhosh Kumar Thatikonda, Leonid Beigelman, Minghong Zhong, Gilles Bignan
  • Substituted thiohydantoin derivatives as androgen receptor antagonists
    Patent number: 10981926
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the antagonism of one or more androgen receptor types. Such compounds are represented by Formula (I) as follows: wherein R1 and G are defined herein.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: April 20, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Gilles Bignan, Peter J. Connolly, Ian Hickson, Lieven Meerpoel, Vineet Pande, Zhuming Zhang, Jonathan Branch, Christian Rocaboy, Luis B. Trabalón Escolar
  • CYCLIC DINUCLEOTIDES AS STING AGONISTS
    Publication number: 20210009630
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein B2, X2, R2a, R2b, R2c, Z-M-Y, Y1-M1Z1, B1, X1, R1a, R1b, R1c are as defined herein.
    Type: Application
    Filed: December 14, 2018
    Publication date: January 14, 2021
    Inventors: Leonid BEIGELMAN, Gilles BIGNAN, Peter J. CONNOLLY, James Patrick EDWARDS, Stuart EMANUEL, Sylvia LAQUERRE, Mark RICHTER, Wim Gert Griet SCHEPENS, Santhosh Kumar THATIKONDA, Johannes Wilhelmus John Fitzgerald THURING, Marcel VIELLEVOYE, Guangyi WANG, Minghong ZHONG
  • Substituted Thiohydantoin Derivatives As Androgen Receptor Antagonists
    Publication number: 20200109150
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the antagonism of one or more androgen receptor types. Such compounds are represented by Formula (I) as follows: wherein R1 and G are defined herein.
    Type: Application
    Filed: November 8, 2019
    Publication date: April 9, 2020
    Inventors: Gilles Bignan, Peter J. Connolly, Ian Hickson, Lieven Meerpoel, Vineet Pande, Zhuming Zhang, Jonathan Branch, Christian Rocaboy, Luis B. Trabalón Escolar
  • CYCLIC DINUCLEOTIDES AS STING AGONISTS
    Publication number: 20190375781
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R1A, R1B, R1C, R1D, B1, R2A, R2B, R2C, R2D, and R2E are defined herein and Formula (II) wherein R1H, R1K, R1J, and R2L are defined herein.
    Type: Application
    Filed: January 26, 2018
    Publication date: December 12, 2019
    Inventors: Stuart Emanuel, Mark Richter, Peter J. Connolly, James Patrick Edwards, Guangyi Wang, Santhosh Kumar Thatikonda, Leonid Beigelman, Minghong Zhong, Gilles Bignan
  • CYCLIC DINUCLEOTIDES AS STING AGONISTS
    Publication number: 20190375782
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R, R1B, R1C, R2B, R2C, B1, W, X, Y, Z are defined herein.
    Type: Application
    Filed: January 26, 2018
    Publication date: December 12, 2019
    Inventors: Stuart Emanuel, Mark Richter, Peter J. Connolly, James Patrick Edwards, Guangyi Wang, Santhosh Kumar Thatikonda, Leonid Beigelman, Minghong Zhong, Gilles Bignan, Wim Schepens, Marcel Viellevoye, Johannes Wilhelmus John Fitzgerald Thuring
  • Substituted thiohydantoin derivatives as androgen receptor antagonists
    Patent number: 10501469
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the antagonism of one or more androgen receptor types. Such compounds are represented by Formula (I) as follows: wherein R1 and G are defined herein.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: December 10, 2019
    Assignee: Janssen Pharmaceutica NV
    Inventors: Gilles Bignan, Peter J. Connolly, Ian Hickson, Lieven Meerpoel, Vineet Pande, Zhuming Zhang, Jonathan Branch, Christian Rocaboy, Luis B. Trabalón Escolar
  • SUBSTITUTED HYDANTOIN AND THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS
    Publication number: 20190337924
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the antagonism of one or more androgen receptor types. Such compounds are represented by Formula (I) as follows: wherein R1a, R2a, R2b, Z, X, Y, and G are defined herein.
    Type: Application
    Filed: June 13, 2019
    Publication date: November 7, 2019
    Inventors: Gilles Bignan, Peter J Connolly, Jan Hickson, Lieven Meerpoel, Vineet Pande, Zhuming Zhang, Jonathan Branch, Christian Rocaboy, Luis B Trabalón Escolar
  • SUBSTITUTED HYDANTOIN AND THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS
    Publication number: 20190330190
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the antagonism of one or more androgen receptor types. Such compounds are represented by Formula (I) as follows: wherein R1, R2a, R2b, Z, X, Y, and G are defined herein.
    Type: Application
    Filed: June 13, 2019
    Publication date: October 31, 2019
    Inventors: Gilles Bignan, Peter J. Connolly, Ian Hickson, Lieven Meerpoel, Vineet Pande, Zhuming Zhang, Jonathan Branch, Christian Rocaboy, Luis B. Trabalón Escolar
  • SUBSTITUTED HYDANTOIN AND THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS
    Publication number: 20190241542
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the antagonism of one or more androgen receptor types. Such compounds are represented by Formula (I) as follows: wherein R1, R2a, R2b, Z, X, Y, and G are defined herein.
    Type: Application
    Filed: April 15, 2019
    Publication date: August 8, 2019
    Inventor: Gilles Bignan
  • THIOHYDANTOIN ANDROGEN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CANCER
    Publication number: 20190209539
    Abstract: Disclosed are compounds, compositions and methods for treating and/or ameliorating diseases, syndromes, disorders, or conditions associated with AR mutant receptors linked to castration-resistant prostate cancer, in a subject, including a mammal and/or human, in need thereof, who has demonstrated resistance to a first or second generation AR antagonist, comprising, consisting of, and/or consisting essentially of, administering to a subject in need thereof, a therapeutically effective amount of a compound of Formula (I) wherein R1, G, R10, and R11 are defined herein.
    Type: Application
    Filed: August 22, 2017
    Publication date: July 11, 2019
    Inventor: Gilles Bignan
  • Substituted Thiohydantoin Derivatives As Androgen Receptor Antagonists
    Publication number: 20180298021
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the antagonism of one or more androgen receptor types. Such compounds are represented by Formula (I) as follows: wherein R1 and G are defined herein.
    Type: Application
    Filed: June 19, 2018
    Publication date: October 18, 2018
    Inventors: Gilles Bignan, Peter J. Connolly, Ian Hickson, Lieven Meerpoel, Vineet Pande, Zhuming Zhang, Jonathan Branch, Christian Rocaboy, Luis B. Trabalón Escolar
  • Substituted thiohydantoin derivatives as androgen receptor antagonists
    Patent number: 10000502
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the antagonism of one or more androgen receptor types. Such compounds are represented by Formula (I) as follows: wherein R1 and G are defined herein.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: June 19, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Gilles Bignan, Peter J Connolly, Ian Hickson, Lieven Meerpoel, Vineet Pande, Zhuming Zhang, Jonathan Branch, Christian Rocaboy, Luis B Trabalón Escolar